Latest Insider Transactions at Avantor, Inc. (AVTR)
This section provides a real-time view of insider transactions for Avantor, Inc. (AVTR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Avantor, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Avantor, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2021
|
Michael Wondrasch EVP & CIO |
SELL
Open market or private sale
|
Direct |
3,036
-2.04%
|
$85,008
$28.71 P/Share
|
|
Feb 25
2021
|
Gerard Brophy EVP, Biopharma Production |
BUY
Grant, award, or other acquisition
|
Direct |
16,281
+7.94%
|
-
|
|
Feb 25
2021
|
Mark Christopher Murray EVP, Biomaterials & AT |
BUY
Grant, award, or other acquisition
|
Direct |
8,140
+29.35%
|
-
|
|
Feb 25
2021
|
Frederic Vanderhaegen EVP, Americas and Europe |
BUY
Grant, award, or other acquisition
|
Direct |
16,281
+6.03%
|
-
|
|
Feb 25
2021
|
Michael Wondrasch EVP & CIO |
BUY
Grant, award, or other acquisition
|
Direct |
8,140
+5.2%
|
-
|
|
Feb 25
2021
|
Justin Miller EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
8,140
+6.28%
|
-
|
|
Feb 25
2021
|
Thomas A Szlosek EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
16,281
+5.63%
|
-
|
|
Feb 25
2021
|
Meghan Henson EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,140
+23.91%
|
-
|
|
Feb 25
2021
|
Devashish Ohri EVP, IMEA |
BUY
Grant, award, or other acquisition
|
Direct |
5,427
+3.36%
|
-
|
|
Feb 25
2021
|
James Bramwell EVP Sales, Customer Excellence |
BUY
Grant, award, or other acquisition
|
Direct |
5,427
+4.3%
|
-
|
|
Feb 25
2021
|
Rakesh Sachdev Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,236
+18.06%
|
-
|
|
Feb 25
2021
|
Christophe Couturier EVP, AMEA |
BUY
Grant, award, or other acquisition
|
Direct |
6,784
+3.86%
|
-
|
|
Feb 25
2021
|
Michael Stubblefield President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
72,359
+4.57%
|
-
|
|
Feb 25
2021
|
Sven Henrichwark EVP, APAC Region |
BUY
Grant, award, or other acquisition
|
Direct |
5,427
+21.51%
|
-
|
|
Feb 25
2021
|
Michael Severino Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,236
+29.54%
|
-
|
|
Feb 25
2021
|
Sheri Lewis EVP, Global Ops & Supply Chain |
BUY
Grant, award, or other acquisition
|
Direct |
13,567
+16.87%
|
-
|
|
Feb 25
2021
|
Rajiv Gupta Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,236
+0.5%
|
-
|
|
Feb 25
2021
|
Christi Shaw Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,236
+28.06%
|
-
|
|
Feb 25
2021
|
Gregory L Summe Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,236
+32.81%
|
-
|
|
Feb 25
2021
|
Juan Andres Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,236
+24.59%
|
-
|
|
Feb 25
2021
|
Jonathan M Peacock Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,236
+4.12%
|
-
|
|
Feb 25
2021
|
Steven W Eck SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,151
+16.09%
|
-
|
|
Feb 24
2021
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
3,059
-1.74%
|
$82,593
$27.93 P/Share
|
|
Feb 24
2021
|
Steven W Eck SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,577
-9.03%
|
$69,579
$27.94 P/Share
|
|
Feb 24
2021
|
Steven W Eck SVP & Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,550
+23.06%
|
-
|
|
Feb 22
2021
|
Thomas A Szlosek EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,980
-1.15%
|
$83,440
$28.69 P/Share
|
|
Feb 22
2021
|
Devashish Ohri EVP, IMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
1,210
-0.8%
|
$33,880
$28.69 P/Share
|
|
Feb 22
2021
|
James Bramwell EVP Sales, Customer Excellence |
SELL
Payment of exercise price or tax liability
|
Direct |
1,216
-1.04%
|
$34,048
$28.69 P/Share
|
|
Feb 22
2021
|
Michael Stubblefield President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,141
-0.7%
|
$283,948
$28.69 P/Share
|
|
Feb 22
2021
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
398
-0.17%
|
$11,144
$28.69 P/Share
|
|
Feb 22
2021
|
Steven W Eck SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
449
-2.2%
|
$12,572
$28.69 P/Share
|
|
Feb 22
2021
|
Justin Miller EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,350
-1.18%
|
$37,800
$28.69 P/Share
|
|
Feb 22
2021
|
Michael Wondrasch EVP & CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,209
-0.85%
|
$33,852
$28.69 P/Share
|
|
Feb 22
2021
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
1,313
-0.8%
|
$36,764
$28.69 P/Share
|
|
Feb 22
2021
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
19,769
-10.13%
|
$553,532
$28.62 P/Share
|
|
Feb 22
2021
|
Gerard Brophy EVP, Biopharma Production |
BUY
Exercise of conversion of derivative security
|
Direct |
19,769
+9.2%
|
$336,073
$17.67 P/Share
|
|
Feb 22
2021
|
Gerard Brophy EVP, Biopharma Production |
SELL
Payment of exercise price or tax liability
|
Direct |
3,072
-1.72%
|
$86,016
$28.69 P/Share
|
|
Feb 05
2021
|
Michael Wondrasch EVP & CIO |
SELL
Open market or private sale
|
Direct |
49,468
-14.15%
|
$1,434,572
$29.77 P/Share
|
|
Feb 05
2021
|
Michael Wondrasch EVP & CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+18.06%
|
$920,000
$23.2 P/Share
|
|
Jan 13
2021
|
Mark Christopher Murray EVP, Biomaterials & AT |
SELL
Payment of exercise price or tax liability
|
Direct |
918
-7.42%
|
$26,622
$29.2 P/Share
|
|
Jan 11
2021
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
378,580
-51.2%
|
$11,357,400
$30.06 P/Share
|
|
Jan 11
2021
|
Gerard Brophy EVP, Biopharma Production |
BUY
Exercise of conversion of derivative security
|
Direct |
378,580
+33.83%
|
$8,707,340
$23.2 P/Share
|
|
Jan 11
2021
|
James Bramwell EVP Sales, Customer Excellence |
SELL
Open market or private sale
|
Direct |
2,505
-2.11%
|
$75,150
$30.0 P/Share
|
|
Jan 06
2021
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
11,509
-6.06%
|
$310,743
$27.24 P/Share
|
|
Jan 04
2021
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
59,418
-23.82%
|
$1,604,286
$27.84 P/Share
|
|
Jan 04
2021
|
Gerard Brophy EVP, Biopharma Production |
BUY
Exercise of conversion of derivative security
|
Direct |
59,418
+19.24%
|
$1,069,524
$18.45 P/Share
|
|
Jan 02
2021
|
Michael Wondrasch EVP & CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,083
-2.65%
|
$114,324
$28.15 P/Share
|
|
Jan 02
2021
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
1,017
-0.43%
|
$28,476
$28.15 P/Share
|
|
Jan 02
2021
|
Thomas A Szlosek EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,135
-3.06%
|
$227,780
$28.15 P/Share
|
|
Jan 02
2021
|
Gerard Brophy EVP, Biopharma Production |
SELL
Payment of exercise price or tax liability
|
Direct |
6,559
-3.34%
|
$183,652
$28.15 P/Share
|